SCHEMBL286441

SCHEMBL286441

COc1cc([N+](=O)[O-])ccc1C=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.62
HTT P42858 2/20 0.62
ALDH1A1 P00352 7/20 0.56
KDM4E B2RXH2 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
CYP3A4 P08684 1/20 0.56
MAPT P10636 1/20 0.56
ALOX15 P16050 1/20 0.56
PRKDC P78527 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PKM P14618 1/20 0.51
PTGS2 P35354 2/20 0.50
TYR P14679 1/20 0.50
CYP19A1 P11511 1/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320420 1.00 ERN1 (0.62) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL4340842 0.87 ERN1 (0.52) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL31597603 0.86 ERN1 (0.62) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL1098465 0.86 ERN1 (0.62) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL12885860 0.85 HTT (0.57) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL12343265 0.85 HTT (0.60) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL3557471 0.85 HTT (0.60) ERN1HTTALDH1A1KDM4ETDP1
SCHEMBL5737354 0.84 ABCB1 (0.50) ERN1HTTALDH1A1KDM4ECYP3A4
SCHEMBL8329402 0.83 ERN1 (0.57) ERN1HTTALDH1A1KDM4ECYP3A4
SCHEMBL27787985 0.83 ERN1 (0.53) ERN1HTTALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119242005-A Production process for biodegradable plastic and application thereof 河北雄安骅洋纸塑包装实业有限公司 2025-01-03 CN claimed
JP-2002523448-A 2002-07-30 JP claimed
US-6410540-B1 HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS SCIOS, INC. 2002-06-25 US claimed
EP-1107758-A2 USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE SCIOS INC. (US) 2001-06-20 EP claimed
WO-2000012074-A2 USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE SCIOS INC. (US) 2000-03-09 WO claimed
US-12630542-B2 Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium ENDOGENA THERAPEUTICS, INC. (US) 2026-05-19 US disclosed
US-12583822-B2 Benzylamine derivative, preparation method therefor and use thereof ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2026-03-24 US disclosed
EP-4707264-A2 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS Verbio SE (DE) 2026-03-11 EP disclosed
EP-4122924-B1 COMPOUNDS AND THE USE THEREOF IN METATHESIS REACTIONS VERBIO SE (DE) 2025-11-19 EP disclosed
EP-3590516-B1 ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2025-09-03 EP disclosed
US-12195452-B2 N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases ENDOGENA THERAPEUTICS, INC. (US) 2025-01-14 US disclosed
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors LEIDOS BIOMEDICAL RESEARCH INC. 2025-01-09 US disclosed
WO-2000025780-A1 COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed
WO-2000026197-A1 NOVEL INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2000-05-11 WO disclosed
EP-0794951-B1 PROCESSES AND INTERMEDIATES FOR PREPARING CIS (+) 3-[4,6-DIHYDROXYCHROMAN-3-YLMETHYL]-4-METHOXYANILINE PFIZER (US) 2000-04-12 EP disclosed
EP-0794951-A1 PROCESSES AND INTERMEDIATES FOR PREPARING CIS(+)3- 4,-6-DIHYDROXYCHROMAN-3-YLMETHYL]-4-METHOXYANILINE Pfizer Hospital Products Group, Inc. (US) 1997-09-17 EP disclosed
US-5539128-A Processes and intermediates for preparing cis(+)3-[4,6-dihydroxy chroman-3-ylmethyl]-4-methoxyaniline PFIZER INC. (US) 1996-07-23 US disclosed
WO-1996016955-A1 PROCESSES AND INTERMEDIATES FOR PREPARING CIS(+)3-[4,-6-DIHYDROXYCHROMAN-3-YLMETHYL]-4-METHOXYANILINE PFIZER INC. (US) 1996-06-06 WO disclosed
US-5208341-A Pressure sensitive copying; thermoreactive or electrochromic recording materials BAYER AKTIENGESELLSCHAFT (DE) 1993-05-04 US disclosed
EP-0480276-A2 Carbonylaminostyrene derivatives as recording material BAYER AG (DE) 1992-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630542-B2 Compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium ALDH1A2, NR2E3, GFRA1 ERN1 2860/4885HTT 1525/4885ALDH1A1 375/4885
US-12195452-B2 N-(4-(oxazol-5-yl)phenyl) chromane-3-carboxamide derivatives and related compounds as stimulators of the production of retinal precursor cells for the treatment of neuroretinal diseases NR2E3, GFRA2, ALDH1A2 ERN1 2255/4885HTT 3177/4885ALDH1A1 1885/4885
US-20250011330-A1 Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors TDP1, TDP2, TOP1 ERN1 286/4885HTT 2185/4885ALDH1A1 769/4885
US-12583822-B2 Benzylamine derivative, preparation method therefor and use thereof CD274, PDCD1, PDCD1LG2 ERN1 4346/4885HTT 3633/4885ALDH1A1 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.